MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2018 International Congress

    Levodopa Effect on Dual-Tasking in Freezing of Gait in Parkinson’s Disease

    E. Bayram, J. Longhurst, S. Banks, Z. Mari, B. Bluett (Las Vegas, NV, USA)

    Objective: To assess the effect of levodopa on dual-tasking in situations triggering freezing of gait (FOG) in Parkinson’s disease (PD). Background: The frequency and severity…
  • 2018 International Congress

    Highly-selective blockade of 5-HT2A receptors with EMD-281,014 reduces the severity of L-DOPA-induced psychosis and dyskinesia in the MPTP-lesioned marmoset model of Parkinson’s disease

    A. Hamadjida, D. Bedard, S. Nuara, J. Gourdon, P. Huot (Montreal, QC, Canada)

    Objective: To investigate the effect of the highly-selective serotonin 2A (5-HT2A) receptor EMD-281,014 on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced psychosis-like behaviours (PLBs) and dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned…
  • 2018 International Congress

    The BlueSky Project: monitoring motor and non-motor characteristics of people with Parkinson’s disease in the laboratory, a simulated apartment, and home and community settings

    K. Erb, J. Daneault, S. Amato, P. Bergethon, C. Demanuele, T. Kangarloo, S. Patel, V. Ramos, D. Volfson, P. Wacnik, H. Zhang, D. Karlin, H. Huggins, L. Soll, G. Costante, G. Vergara-Diaz, F. Parisi, J. Banghu, C. Brooks, C. Dethridge, A. Abrami, E. Bilal, V. Caravagio, S. Heisig, R. Norel, E. Pissadaki, J. Rice, B. Ho, K. Thomas, P. Bonato (Cambridge, MA, USA)

    Objective: We present data collected for the BlueSky Project which aims to develop novel assessments of motor and non-motor function using mobile and wearable technology.…
  • 2018 International Congress

    Quantitative Keyboard Tapping Measurement Correlates with Electrophysiological Changes in STN LFPs of PD Patients Treated with L-dopa Better Than UPDRS Subscores

    M. Ozturk, A. Abosch, D. Francis, J. Wu, N. Ince (Houston, TX, USA)

    Objective: Reliable and objective assessment of the symptoms of patients with Parkinson’s disease (PD) and the correlation of the measures with neural patterns is important…
  • 2017 International Congress

    Parkinsonism in the very old – A clinicopathological study

    A. Rajput, E. Rajput (Saskatoon, SK, Canada)

    Objective: To identify, spectrum of Parkinson variants, clinical features and course of disease in age > 80 year onset cases. Background: Old age is the…
  • 2017 International Congress

    Interim Results of an Ongoing Open-label Safety Study of ADS-5102 (amantadine hydrochloride) Extended-Release Capsules for Treatment of Levodopa-Induced Dyskinesia (LID) (EASE LID 2 Study)

    R. Hauser, R. Pahwa, C. Tanner, W. Oertel, S. Isaacson, M.J. Stempien, L. Felt, R. Johnson (Tampa, FL, USA)

    Objective: Characterize the long-term safety and tolerability of 340 mg of ADS-5102 administered once daily at bedtime, for the treatment of LID in Parkinson’s disease…
  • 2017 International Congress

    Post-hoc analyses of the recommended starting dose for Rytary based on “off” time

    N. Modi, S. Khanna, S. Gupta (Hayward, CA, USA)

    Objective: To determine whether correcting for “off” time duration improves the selection of the final LD dose when converting to extended-release carbidopa-levodopa capsules (ER CD-LD,…
  • 2017 International Congress

    Compulsive sexual behaviour in Parkinson’s disease is associated with higher doses of levodopa

    P. Barbosa, T. Warner, A. Djamshidian (London, United Kingdom)

    Objective: To assess whether compulsive sexual behaviour in individuals with PD is associated with higher doses of levodopa.  Background: The lifetime prevalence of compulsive sexual behaviour…
  • 2017 International Congress

    Dopamine substitution restores effective connectivity between prefrontal and premotor areas in Parkinson’s disease

    P. Loehrer, F. Nettersheim, F. Jung, I. Weber, C. Huber, T. Dembek, E. Pelzer, M. Tittgemeyer, L. Timmermann (Marburg, Germany)

    Objective: To assess influences of dopamine deficiency on the causal interplay within the motor network during bimanual finger tapping in Parkinson's disease (PD) patients. Background:…
  • 2017 International Congress

    Polyneuropathy in patients with Parkinson’s disease from southern Spain treatment with levodopa/carbidopa intestinal gel infusión

    F. Carrillo, S. Jesus, L. Vargas, M. Bernal, M.T. Caceres, A.D. Adarmes, M. Carballo, P. Mir (Seville, Spain)

    Objective: This study main objective is to prospectively report the 10-year incidence of polineuropathy in Parkinson´s disease patients from southern Spain treated with LCIG. Background: Patients with…
  • « Previous Page
  • 1
  • …
  • 47
  • 48
  • 49
  • 50
  • 51
  • …
  • 62
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley